Cardiol Therapeutics Inc. With a team of experienced and dedicated individuals, Cardiol is committed to advancing research and clinical development of anti-inflammatory and anti-fibrotic treatments for heart disease. Their lead drug candidate, CardiolRx™, is an oral solution of cannabidiol that is pharmaceutically manufactured and currently in clinical development for the treatment of heart disease.

Cannabidiol, the key component of CardiolRx™, has been found to inhibit the activation of the inflammasome pathway, a crucial process in the development and progression of inflammation and fibrosis associated with conditions like myocarditis, pericarditis, and heart failure. Cardiol has achieved authorization from the United States Food and Drug Administration to conduct clinical studies on CardiolRx™. These studies aim to evaluate the drug's efficacy and safety in treating two heart diseases: recurrent pericarditis and myocarditis.

With a strong commitment to improving cardiac health, Cardiol Therapeutics Inc. Learn more about their groundbreaking work and research on their website